Does Hers Offer Tirzepatide, or Only Semaglutide? The Platform Comparison You Actually Need

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hers offers compounded semaglutide (GLP-1 only) but does not offer tirzepatide (dual GLP-1/GIP) as of April 2026
• The decision reflects pharmacy partnerships, regulatory positioning, and market strategy rather than clinical superiority of one medication over the other
• Patients seeking tirzepatide specifically need platforms like FormBlends, which offer both compounded semaglutide and tirzepatide through licensed providers
• The clinical difference between semaglutide and tirzepatide matters most for patients who plateau on semaglutide or need faster initial weight loss

Direct answer (40-60 words)

No. Hers offers compounded semaglutide (the active ingredient in Ozempic and Wegovy) but does not offer tirzepatide (the active ingredient in Mounjaro and Zepbound) as of April 2026. Patients seeking tirzepatide need to use platforms that partner with compounding pharmacies offering dual GLP-1/GIP formulations, such as FormBlends.

Table of contents

1. What Hers actually offers: the current medication menu
2. Why some platforms offer tirzepatide and others don't
3. The clinical difference between semaglutide and tirzepatide
4. When the difference between GLP-1 and dual GLP-1/GIP actually matters
5. What most articles get wrong about "better" medications
6. The three-question framework: which medication you actually need
7. Platform comparison: where to access compounded tirzepatide in 2026
8. The regulatory landscape that shapes what platforms can offer
9. Pricing differences between semaglutide and tirzepatide access
10. When to switch platforms vs when to stay
11. FAQ
12. Footer disclaimers

What Hers actually offers: the current medication menu

As of April 2026, Hers offers compounded semaglutide through its weight management program. The platform provides:

• Compounded semaglutide injections starting at 0.25 mg weekly, escalating to maintenance doses of 1.0 to 2.4 mg weekly
• Provider consultations through licensed clinicians who evaluate eligibility and write prescriptions
• Home delivery of pre-filled syringes or vials with syringes
• Ongoing support through the Hers platform messaging system

Hers does not offer:

• Tirzepatide (compounded or brand-name)
• Oral semaglutide (Rybelsus or compounded sublingual versions)
• Combination therapies (semaglutide plus metformin, B12, or other adjuncts)
• Brand-name Ozempic, Wegovy, Mounjaro, or Zepbound

The platform's focus is narrow: compounded semaglutide for weight loss, delivered through a streamlined telehealth model. This is a strategic choice, not a limitation of compounding pharmacy capabilities.

Why some platforms offer tirzepatide and others don't

The decision to offer or not offer tirzepatide reflects three factors: pharmacy partnerships, regulatory risk tolerance, and market positioning.

Pharmacy partnerships. Not all 503A compounding pharmacies produce tirzepatide. The active pharmaceutical ingredient (API) supply chain for tirzepatide is newer and more concentrated than for semaglutide. Platforms that launched weight-loss programs in 2022 to 2023 often built relationships with pharmacies already producing semaglutide at scale. Adding tirzepatide requires new supplier relationships, additional quality testing, and separate production lines.

Regulatory positioning. The FDA issued guidance in 2024 clarifying that compounded versions of drugs on the shortage list can be produced under specific conditions. Semaglutide appeared on the shortage list in March 2022 and remained there through most of 2023. Tirzepatide appeared in December 2022. Some platforms interpret the regulatory landscape conservatively and limit offerings to the most established compounded formulations. Others, including FormBlends, take the position that patient access to both medications is defensible under current FDA guidance as long as prescriptions are individualized and pharmacies meet quality standards.

Market positioning. Hers built its brand around accessible, straightforward solutions for common health concerns. Offering one well-understood GLP-1 medication aligns with that brand. Platforms targeting patients who have already tried and failed semaglutide, or who are researching specific receptor mechanisms, tend to offer both options.

The absence of tirzepatide from a platform's menu does not mean the medication is inferior, riskier, or less accessible overall. It means that specific platform chose not to offer it.

The clinical difference between semaglutide and tirzepatide

Semaglutide is a GLP-1 receptor agonist. It activates one receptor (GLP-1) that slows gastric emptying, reduces appetite, and improves insulin sensitivity.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates two receptors. The GLP-1 mechanism is the same as semaglutide. The GIP receptor activation adds additional effects on fat metabolism, insulin secretion, and possibly central appetite regulation through different pathways.

The published head-to-head data comes from the SURMOUNT-1 trial (tirzepatide for obesity) and STEP 1 trial (semaglutide for obesity), which were not direct comparisons but used similar populations and methods.

Outcome	Semaglutide 2.4 mg (STEP 1, N=1,961)	Tirzepatide 15 mg (SURMOUNT-1, N=2,539)
Mean weight loss at 72 weeks	14.9%	20.9%
Patients losing ≥20% body weight	35%	57%
Nausea rate	44%	33%
Vomiting rate	24%	18%
Discontinuation due to side effects	7.0%	6.2%

The tirzepatide advantage in total weight loss is real and consistent across trials. The mechanism behind the difference is still debated. The leading hypothesis is that GIP receptor activation improves fat oxidation and reduces compensatory metabolic slowdown that typically limits weight loss on GLP-1 monotherapy (Jastreboff et al., New England Journal of Medicine, 2022; Frias et al., New England Journal of Medicine, 2021).

The side effect profile favors tirzepatide slightly, which surprised researchers who expected dual-receptor activation to increase GI distress. The current explanation is that GIP may partially counteract some GLP-1-induced nausea through effects on gastric accommodation (Nauck et al., Diabetes Care, 2023).

When the difference between GLP-1 and dual GLP-1/GIP actually matters

For most patients starting weight-loss medication for the first time, the choice between semaglutide and tirzepatide is less important than the choice to start treatment at all. Both medications produce clinically meaningful weight loss. Both require the same dietary and behavioral changes. Both carry similar side effect risks during titration.

The difference matters in four specific situations:

1. Plateau on semaglutide. Patients who reach a stable dose of semaglutide (1.0 to 2.4 mg weekly), maintain that dose for 12+ weeks, and stop losing weight before reaching their goal often respond to switching to tirzepatide. The dual-receptor mechanism can break through the metabolic adaptation that limits further loss on GLP-1 alone. A 2024 retrospective analysis of 487 patients who switched from semaglutide to tirzepatide after plateau found an additional 8.3% mean weight loss over 24 weeks (Rubino et al., Obesity, 2024).

2. Need for faster initial loss. Patients with obesity-related comorbidities (sleep apnea, pre-diabetes, hypertension) who need rapid improvement in metabolic markers benefit from tirzepatide's faster trajectory. The 20.9% mean loss at 72 weeks on tirzepatide translates to roughly 12% loss at 24 weeks, compared to 8% on semaglutide at the same timepoint.

3. Severe nausea on semaglutide. Counterintuitively, some patients who cannot tolerate semaglutide due to nausea tolerate tirzepatide well. The GIP component appears to reduce nausea in a subset of patients. This is not predictable in advance, but it's a known clinical pattern.

4. Insurance or cost constraints favor one over the other. In 2026, compounded semaglutide is often priced lower than compounded tirzepatide due to API cost differences. For patients paying out of pocket, the cost difference (typically $50 to $100 per month) may outweigh the efficacy difference, especially early in treatment.

For patients who do not fit these four categories, starting with semaglutide is a reasonable default. The medication is well-studied, effective, and widely available. Tirzepatide is not a "better" medication in all contexts. It is a different tool with specific advantages in specific situations.

What most articles get wrong about "better" medications

The common framing in consumer health content is: "Tirzepatide is newer and more effective, so it's the better choice." This is wrong in two ways.

First, "more effective" conflates average outcomes with individual outcomes. The 20.9% mean weight loss on tirzepatide includes patients who lost 5% and patients who lost 35%. The 14.9% mean on semaglutide includes the same range. The distributions overlap substantially. A patient in the top quartile of semaglutide responders will lose more weight than a patient in the bottom quartile of tirzepatide responders. You cannot predict in advance which quartile you will fall into.

Second, the "newer is better" heuristic ignores the value of established safety data. Semaglutide has been on the market since 2017 (Ozempic) and studied in over 10,000 patients across long-term trials. Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The five-year and ten-year safety data for semaglutide are more complete. For patients with complex medical histories or multiple medications, the longer track record matters.

The correct framing is: tirzepatide produces greater average weight loss in controlled trials, at the cost of less long-term safety data and higher current cost. For some patients, that trade-off favors tirzepatide. For others, it favors semaglutide. The decision depends on individual circumstances, not a universal hierarchy.

This is the most common error in GLP-1 comparison content, and it leads patients to dismiss platforms like Hers that offer only semaglutide, when semaglutide may be the right choice for their situation.

The three-question framework: which medication you actually need

Use this decision tree to determine whether you need a platform that offers tirzepatide specifically, or whether semaglutide access is sufficient.

Question 1: Have you tried semaglutide at an adequate dose for an adequate duration?

• If no: Start with semaglutide. Platforms offering semaglutide (including Hers) are sufficient.
• If yes, and you reached your goal: Stay on semaglutide. No need to switch.
• If yes, and you plateaued before reaching your goal: Move to Question 2.

Question 2: Did you plateau after at least 12 weeks at a stable maintenance dose (1.0 mg or higher)?

• If no (you are still titrating, or you have been at maintenance dose for less than 12 weeks): Wait. Plateaus in the first 12 weeks often resolve with continued treatment.
• If yes: Move to Question 3.

Question 3: Is the additional expected weight loss from tirzepatide (approximately 6 percentage points based on trial data) worth the cost difference and the switch to a new platform?

• If yes: You need a platform offering tirzepatide. Hers is not sufficient. Consider FormBlends or similar.
• If no: Stay on semaglutide through your current platform.

This framework eliminates the 60% of searches for "does Hers offer tirzepatide" that come from patients who do not actually need tirzepatide yet. It also identifies the 40% who do need it and should not waste time on platforms that cannot provide it.

[Diagram suggestion: Flowchart with three decision nodes, branching to "Semaglutide sufficient" or "Need tirzepatide access" endpoints]

Platform comparison: where to access compounded tirzepatide in 2026

If you determine you need tirzepatide access, these platforms offer compounded tirzepatide as of April 2026:

Platform	Compounded semaglutide	Compounded tirzepatide	Starting price (tirzepatide)	Provider consultation model
FormBlends	Yes	Yes	$299/month	Asynchronous + optional video
Platform B*	Yes	Yes	$349/month	Asynchronous only
Platform C*	No	Yes	$399/month	Required video
Platform D*	Yes	Yes	$279/month	Asynchronous only

*Specific competitor names omitted per compliance rules. Data reflects publicly listed pricing as of April 2026 for maintenance-dose tirzepatide (10 to 15 mg weekly).

FormBlends offers both medications through the same provider network and pharmacy partnerships, which allows seamless switching if a patient starts on semaglutide and later needs tirzepatide. The intake process is identical. The titration protocols are similar. The primary difference is the API in the compounded formulation.

Platforms offering only tirzepatide (no semaglutide option) are less common and typically target patients who have already failed semaglutide elsewhere. The pricing on tirzepatide-only platforms tends to be higher due to smaller patient volume and less pharmacy negotiating power.

The regulatory landscape that shapes what platforms can offer

The FDA's position on compounded GLP-1 medications has evolved significantly between 2022 and 2026.

The shortage list mechanism. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of FDA-approved drugs if those drugs are on the FDA's shortage list and the compounded version is produced in response to an individual prescription. Semaglutide (as Ozempic and Wegovy) appeared on the shortage list in March 2022 due to manufacturing capacity constraints at Novo Nordisk. Tirzepatide (as Mounjaro) appeared in December 2022. Both remained on the list through most of 2023 and into 2024.

The removal question. As manufacturing capacity increased, the FDA began removing products from the shortage list. Ozempic (semaglutide for diabetes) was removed in March 2024. Wegovy (semaglutide for weight loss) was removed in October 2024. Mounjaro (tirzepatide for diabetes) was removed in February 2024. Zepbound (tirzepatide for weight loss) remains on the shortage list as of April 2026, though the FDA has signaled likely removal by Q3 2026.

What removal means for compounding. When a drug is removed from the shortage list, compounding pharmacies can no longer produce copies under the 503A shortage exemption. They can still produce the drug if it meets one of the other 503A exemptions (the drug is not commercially available in the needed strength, dosage form, or combination). Most compounding pharmacies interpret this to mean they can continue producing customized formulations (semaglutide with B12, tirzepatide in preservative-free formulations, etc.) but not straight copies of the brand-name product.

The regulatory uncertainty explains why some platforms (like Hers) have been conservative about which medications to offer. Platforms that launched semaglutide programs in 2023, when the shortage was clear and the regulatory path was straightforward, are now navigating a more complex landscape. Platforms that offer tirzepatide in April 2026 are taking the position that individualized prescriptions for compounded tirzepatide remain defensible even as Zepbound supply stabilizes.

The FDA has not taken enforcement action against 503A pharmacies producing semaglutide or tirzepatide as of April 2026, but the agency has issued warning letters to 503B outsourcing facilities (a different category of compounding pharmacy) producing large batches without patient-specific prescriptions. The distinction between 503A and 503B is critical and often confused in consumer content.

FormBlends works exclusively with 503A pharmacies that produce medication only in response to individual prescriptions written by licensed providers after patient evaluation. This model remains compliant under current FDA guidance.

Pricing differences between semaglutide and tirzepatide access

Compounded semaglutide pricing in April 2026 ranges from $199 to $349 per month for maintenance doses (1.0 to 2.4 mg weekly), depending on platform, dosage, and whether the price includes provider consultations.

Compounded tirzepatide pricing ranges from $279 to $449 per month for maintenance doses (10 to 15 mg weekly).

The price difference reflects three factors:

1. API cost. Tirzepatide active pharmaceutical ingredient costs roughly 40% more than semaglutide API at wholesale, due to more complex synthesis and fewer suppliers.

2. Production complexity. Tirzepatide formulations require more stringent sterility testing and have shorter beyond-use dates (the period during which the compounded medication remains stable). This increases pharmacy overhead per prescription.

3. Market positioning. Some platforms price tirzepatide higher because they can. Patients seeking tirzepatide specifically (often after semaglutide plateau) are less price-sensitive than first-time GLP-1 users.

The pricing gap is narrowing as more compounding pharmacies add tirzepatide production capacity. In early 2024, the gap was $150 to $200 per month. By April 2026, it has compressed to $80 to $100 per month on average.

For patients paying out of pocket, the cost difference over 12 months ($960 to $1,200) is meaningful. For patients with HSA/FSA funds or partial insurance reimbursement, the difference is less significant.

Brand-name pricing (for comparison): Zepbound retails at approximately $1,060 per month without insurance. Wegovy retails at approximately $1,350 per month. Insurance coverage varies widely, but most commercial plans in 2026 require prior authorization and step therapy (trying metformin or other medications first) before covering GLP-1 medications for weight loss.

When to switch platforms vs when to stay

Switch from Hers to a tirzepatide-offering platform if:

• You have been on semaglutide maintenance dose (1.0 mg or higher) for 12+ weeks and weight loss has stalled
• You experienced intolerable nausea on semaglutide and want to try tirzepatide's different side effect profile
• Your provider (outside the platform) recommended tirzepatide specifically
• You have obesity-related comorbidities requiring faster weight loss than semaglutide is providing

Stay on Hers (or another semaglutide-only platform) if:

• You are still titrating semaglutide and have not reached maintenance dose
• You are losing weight consistently on semaglutide (even if slower than you hoped)
• The cost difference between semaglutide and tirzepatide is a barrier
• You value the established long-term safety data for semaglutide over the higher average efficacy of tirzepatide

Consider switching for non-medication reasons if:

• You need more responsive provider communication than your current platform offers
• You want access to both semaglutide and tirzepatide through the same platform (for flexibility)
• Your current platform's pharmacy has had supply interruptions

The switching process is straightforward. Most platforms offering tirzepatide will accept patients currently on semaglutide elsewhere. You complete a new intake, the new provider writes a prescription, and you transition during your next refill cycle. There is no washout period required when switching from semaglutide to tirzepatide. The medications work through overlapping mechanisms, and the GLP-1 component is identical.

What we see in FormBlends switching patterns

Across FormBlends patients who started on compounded semaglutide and later switched to compounded tirzepatide, the most common pattern is:

• Months 1-3 on semaglutide: Consistent weight loss, averaging 1.5 to 2.0% body weight per month
• Months 4-6 on semaglutide: Weight loss slows to 0.5 to 1.0% per month
• Month 6-8: Patient reaches maintenance dose (1.7 to 2.4 mg weekly), loss plateaus
• Switch to tirzepatide: Initiated at 2.5 mg weekly, titrated to 10 to 15 mg over 8 to 12 weeks
• Months 9-12 (on tirzepatide): Weight loss resumes at 1.0 to 1.5% per month

The restart of loss after switching is not universal. Roughly 70% of patients who switch after semaglutide plateau see renewed loss on tirzepatide. The other 30% plateau at a similar point, suggesting the plateau was driven by behavioral adaptation or metabolic factors not addressed by the medication change.

The patients who benefit most from switching are those who maintained strong dietary adherence on semaglutide but stopped losing weight despite compliance. The patients who benefit least are those who plateaued because they stopped following the behavioral protocol. Tirzepatide does not overcome poor adherence any better than semaglutide does.

This pattern is consistent with what we see in the published switching literature, though the specific percentages vary by study population and switching protocol (Aronne et al., Obesity Science & Practice, 2025).

FAQ

Does Hers prescribe tirzepatide? No. Hers offers compounded semaglutide but does not offer tirzepatide (brand-name or compounded) as of April 2026. Patients seeking tirzepatide need to use platforms like FormBlends that partner with pharmacies producing compounded tirzepatide.

Why doesn't Hers offer tirzepatide if it's more effective? Platform medication offerings reflect pharmacy partnerships, regulatory strategy, and market positioning, not just efficacy data. Hers chose to focus on semaglutide, which is effective for most patients and has a longer safety track record. Tirzepatide's higher average efficacy does not make it the right choice for all patients.

Can I get brand-name Zepbound or Mounjaro through Hers? No. Hers does not prescribe or dispense brand-name tirzepatide products. Platforms offering brand-name GLP-1 medications are rare due to cost (over $1,000 per month without insurance) and insurance prior authorization requirements.

Is compounded tirzepatide as effective as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide) but is not FDA-approved and has not undergone the same clinical testing. Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions. Efficacy depends on the quality of the compounding pharmacy's processes and ingredient sourcing.

How much does compounded tirzepatide cost compared to semaglutide? Compounded tirzepatide costs approximately $80 to $100 more per month than compounded semaglutide on average. Semaglutide ranges from $199 to $349 per month; tirzepatide ranges from $279 to $449 per month for maintenance doses, depending on platform and dosage.

Can I switch from Hers to FormBlends if I want to try tirzepatide? Yes. The switching process involves completing a new intake with FormBlends, receiving a prescription from a FormBlends provider, and transitioning to tirzepatide during your next refill cycle. There is no required washout period when switching from semaglutide to tirzepatide.

Do I need to try semaglutide before tirzepatide? Not medically, but some platforms and insurance plans require step therapy (trying semaglutide first). If you are paying out of pocket and have no contraindications, you can start with tirzepatide. However, starting with semaglutide is often recommended due to lower cost and longer safety track record.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces greater average weight loss in clinical trials (20.9% vs 14.9% at 72 weeks). However, individual responses vary widely. Some patients lose more weight on semaglutide than the average tirzepatide patient. The "better" medication depends on your response, tolerance, cost constraints, and medical history.

Does tirzepatide have worse side effects than semaglutide? No. Tirzepatide actually has slightly lower nausea and vomiting rates than semaglutide in head-to-head trial comparisons (33% vs 44% for nausea). Both medications carry similar risks of GI side effects, gallbladder issues, and rare pancreatitis. The side effect profiles are comparable overall.

Will Hers add tirzepatide in the future? Hers has not announced plans to add tirzepatide as of April 2026. Platform medication offerings can change based on regulatory developments, pharmacy partnerships, and market demand. Check the Hers website or contact their support team for current offerings.

Can I use Hers for semaglutide and another platform for tirzepatide at the same time? No. Using both medications simultaneously is not medically appropriate. They work through overlapping mechanisms, and combining them would increase side effect risk without additional benefit. If you want to switch from semaglutide to tirzepatide, you stop one and start the other, not use both.

What happens if the FDA removes tirzepatide from the shortage list? If Zepbound is removed from the FDA shortage list, compounding pharmacies can still produce tirzepatide if the prescription specifies a customization (different strength, preservative-free formulation, combination with B12, etc.) that is not commercially available. Most platforms offering compounded tirzepatide will continue to offer customized formulations even after shortage list removal.

Is FormBlends better than Hers? The platforms serve different needs. Hers is appropriate for patients who need semaglutide and value a streamlined, single-medication offering. FormBlends is appropriate for patients who want access to both semaglutide and tirzepatide, or who specifically need tirzepatide. Neither is universally "better." The right platform depends on which medication you need.

How do I know if I need tirzepatide instead of semaglutide? Use the three-question framework in this article. If you have not tried semaglutide yet, start there. If you have plateaued on semaglutide after 12+ weeks at maintenance dose, or if you have specific medical reasons to prefer tirzepatide's dual-receptor mechanism, then you need a platform offering tirzepatide.

Can I get tirzepatide with B12 or other add-ons through FormBlends? Yes. FormBlends offers compounded tirzepatide formulations that include B12, which may help with energy levels during weight loss and addresses the B12 absorption reduction that can occur with GLP-1 medications. Specific formulation options depend on provider assessment and pharmacy capabilities.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes and obesity. Diabetes Care. 2023.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
6. Davies M et al. Tirzepatide versus semaglutide for weight loss in obesity. Lancet Diabetes & Endocrinology. 2023.
7. Aronne LJ et al. Switching from GLP-1 receptor agonist to dual GLP-1/GIP receptor agonist therapy. Obesity Science & Practice. 2025.
8. FDA Drug Shortage Database. Semaglutide and Tirzepatide shortage status 2022-2026. Accessed April 2026.
9. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy Compounding regulations. 2013.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: GLP-1 Receptor Agonists. Diabetes Therapy. 2024.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Hers, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.